There are currently 939 clinical trials in Durham, North Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including Duke University Medical Center, Duke University, Duke Comprehensive Cancer Center and Duke University Health System. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
NCT05710848
Recruiting
This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: Duke Cancer Center, Durham, North Carolina
Conditions: Non-muscle-invasive Bladder Cancer
Register for Updates
Vincristine Pharmacokinetics in Infants
NCT05359237
Recruiting
This pilot trial compares drug exposure levels using a new method for dosing vincristine in infants and young children compared to the standard dosing method based on body surface area (BSA) in older children. Vincristine is an anticancer drug used to a variety of childhood cancers. The doses anticancer drugs in children must be adjusted based on the size of the child because children vary significantly in size (height, weight, and BSA) and ability to metabolize drugs from infancy to adolescence... Read More
Gender:
ALL
Ages:
12 years and below
Trial Updated:
12/02/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Register for Updates
A Study to Learn About How a New Pneumococcal Vaccine Works in Children
NCT06531538
Recruiting
The purpose of this study is to learn about the safety, tolerability and immune effects of a pneumococcal vaccine in toddlers. Participants will take part in this study for approximately 6 or 8 months depending on which group they are assigned to. During this time participants will have 2 clinic visits and 1 phone visit for the 1-Dose group, or 3 clinic visits and 1 phone visit for the 2-Dose group. At these clinic visits, participants will be asked if any side effects were experienced. The pa... Read More
Gender:
ALL
Ages:
Between 12 months and 15 months
Trial Updated:
12/02/2024
Locations: Duke Vaccine and Trials Unit, Durham, North Carolina +1 locations
Conditions: Pneumococcal Disease
Register for Updates
Daratumumab in Primary Antiphospholipid Syndrome
NCT05671757
Recruiting
The purpose of this study is to see if the study medication, daratumumab, is safe to treat individuals with Anti-Phospholipid Syndrome (APS). Three daratumumab dosing cohorts are planned with up to six participants in each dosing cohort with the potential to enroll an additional 4 subjects in the highest safe dose (HSD) cohort, for a total of up to 22 participants. The dosing cohorts are: 4 mg/kg, 8 mg/kg, and 16 mg/kg. Each cohort will receive intravenous (IV) administration of daratumumab acc... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/26/2024
Locations: Duke University, Durham, North Carolina
Conditions: Autoimmune Disorders
Register for Updates
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373
Recruiting
The purpose of this study is to determine the safety and efficacy of brepocitinib in participants with active, non-anterior (intermediate, posterior, or pan) non-infectious uveitis (NIU).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/25/2024
Locations: Clinical Trial Site, Durham, North Carolina
Conditions: Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Register for Updates
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
NCT03860883
Recruiting
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Cutaneous Melanoma, Stage II
Register for Updates
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
NCT04916210
Recruiting
The overall goal of the DISCOVERY study is to better understand what factors contribute to changes in cognitive (i.e., thinking and memory) abilities in patients who experienced a stroke. The purpose of the study is to help doctors identify patients at risk for dementia (decline in memory, thinking and other mental abilities that significantly affects daily functioning) after their stroke so that future treatments may be developed to improve outcomes in stroke patients. For this study, a "stroke... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Ischemic Stroke, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Dementia, Vascular, Mild Cognitive Impairment, Vascular Cognitive Impairment
Register for Updates
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
NCT04337177
Recruiting
A pilot pharmacokinetic trial to determine the safety and efficacy of a flavored, orally administered irinotecan VAL-413 (Orotecan®) given with temozolomide for treatment of recurrent pediatric solid tumors including but not limited to neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, hepatoblastoma and medulloblastoma
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
11/24/2024
Locations: Duke University Children's Hospital and Health Center, Durham, North Carolina
Conditions: Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Hepatoblastoma, Medulloblastoma
Register for Updates
A Study of ZN-c3 in Patients With Ovarian Cancer
NCT04516447
Recruiting
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/22/2024
Locations: Site 0259, Durham, North Carolina
Conditions: Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Register for Updates
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
NCT05354141
Recruiting
To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/21/2024
Locations: Direct Biologics Investigational Site, Durham, North Carolina
Conditions: Acute Respiratory Distress Syndrome, ARDS
Register for Updates
REmotely Monitored, Mobile Health Supported Multidomain Rehabilitation Program With High Intensity Interval Training for COVID-19
NCT05218083
Recruiting
Multicenter, prospective, randomized controlled trial providing mobile health supported physical rehabilitation to 120 patients who have been critically ill with COVID-19 and who complete at least one exercise session.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: Duke University Health System, Durham, North Carolina
Conditions: COVID-19, Critical Illness, ICU Acquired Weakness, PICS, Cardiorespiratory Fitness
Register for Updates
ADRC Clinical Cohort (Alzheimer's Disease)
NCT06703541
Recruiting
The purpose of the study is to establish a clinical cohort for the Duke/UNC Alzheimer's Disease Research Center (ADRC). The cohort will be composed of subjects ages 25 to 44 at enrollment with normal cognition and subjects ages 45 to 80 at enrollment with normal cognition, mild cognitive impairment, or a dementia diagnosis. Initial data including demographics, medical and family history, physical exam, and neuropsychological testing will be obtained. Participants will be asked to contribute a bl... Read More
Gender:
ALL
Ages:
Between 25 years and 80 years
Trial Updated:
11/21/2024
Locations: Duke University, Durham, North Carolina
Conditions: Alzheimer Disease, Mild Cognitive Impairment, Dementia
Register for Updates